posted on 2023-06-22, 04:44authored byR Haartsen, T Charman, G Pasco, MH Johnson, EJH Jones, S Baron-Cohen, R Bedford, A Blasi, P Bolton, S Chandler, C Cheung, K Davies, M Elsabbagh, J Fernandes, I Gammer, H Garwood, T Gliga, J Guiraud, Kristelle HudryKristelle Hudry, M Liew, S Lloyd-Fox, H Maris, L O’Hara, A Pickles, H Ribeiro, E Salomone, L Tucker, A Volein
Theta oscillations (spectral power and connectivity) are sensitive to the social content of an experience in typically developing infants, providing a possible marker of early social brain development. Autism is a neurodevelopmental condition affecting early social behaviour, but links to underlying social brain function remain unclear. We explored whether modulations of theta spectral power and connectivity by naturalistic social content in infancy are related to family history for autism. Fourteen-month-old infants with (family history; FH; N = 75) and without (no family history; NFH; N = 26) a first-degree relative with autism watched social and non-social videos during EEG recording. We calculated theta (4–5 Hz) spectral power and connectivity modulations (social–non-social) and associated them with outcomes at 36 months. We replicated previous findings of increased theta power and connectivity during social compared to non-social videos. Theta modulations with social content were similar between groups, for both power and connectivity. Together, these findings suggest that neural responses to naturalistic social stimuli may not be strongly altered in 14-month-old infants with family history of autism.
Funding
This research was supported by a grant from the European Community's Horizon 2020 Program under grant agreement n degrees 642990 (Brainview)(RH, TC, MJ, EJ: analysis, interpretation of the data, and writing the manuscript), and the Birkbeck Wellcome Trust Institutional Strategic Support Fund (ISSF2), grant ref 204770/Z/16/Z (RH: analysis, interpretation of the data, and writing the manuscript); the Innovative Medicines Initiative Joint Undertaking under grant agreement n degrees 115300, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007 -2013) and EFPIA companies' in kind contribution (TC, GP, EJ, MJ: design of the study and data collection); and the UK Medical Research Council (G0701484 & MR/K021389/1), and the BASIS funding consortium led by Autistica (www.basisnetwork.org) (TC, GP, MJ, EJ, TBT: design of the study and data collection). The results leading to this publication have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI (RH, TC, GP, MJ, EJ: analysis, interpretation of the data, and writing the manuscript).